Processa Pharmaceuticals (PCSA) Other Non Operating Income (2016 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Other Non Operating Income came in at -$45965.0 in Q1 2026, down 465.24% YoY from $12585.0 in Q1 2025, and down 103.82% on a QoQ basis from $1.2 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Other Non Operating Income (2016 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 9 years of Other Non Operating Income data on file, last reported at -$45965.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 465.24% year-over-year to -$45965.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 2004.55% YoY) and the FY2025 annual result came in at $1.3 million, up 20466.59% from the prior year.
- Other Non Operating Income fell to -$45965.0 in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.2 million in Q4 2025 to a low of -$188818.0 in Q4 2024.
- A 5-year average of $110723.2 and a median of $40150.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income surged 5172.39% — and 2026, when it sank 465.24%.
- Tracing PCSA's Other Non Operating Income over 5 years: stood at $7380.0 in 2022, then jumped by 1280.76% to $101900.0 in 2023, then slumped by 285.3% to -$188818.0 in 2024, then soared by 737.16% to $1.2 million in 2025, then tumbled by 103.82% to -$45965.0 in 2026.
- The last three Other Non Operating Income figures came in at -$45965.0 (Q1 2026), $1.2 million (Q4 2025), and $52270.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45,965.00 |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 52,270.00 |
| Jun 30, 2025 | 16,865.00 |
| Mar 31, 2025 | 12,585.00 |
| Dec 31, 2024 | -188,818.00 |
| Sep 30, 2024 | 40,150.00 |
| Jun 30, 2024 | 71,698.00 |
| Mar 31, 2024 | 83,217.00 |
| Jun 30, 2023 | 101,900.00 |
| Mar 31, 2023 | 83,462.00 |
| Jun 30, 2022 | 7,380.00 |
| Mar 31, 2022 | 1,583.00 |
| Sep 30, 2020 | -186,197.00 |
| Sep 30, 2019 | -768.00 |
| Sep 30, 2017 | 5,447.00 |
| Jun 30, 2017 | 30,912.00 |
| Dec 31, 2016 | -20,424.00 |
| Jun 30, 2016 | 25,155.00 |